BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
Keyword: Metabolic dysfunction-associated fatty liver disease
1
Carnitine palmitoyltransferase-II inactivity promotes malignant progression of metabolic dysfunction-associated fatty liver disease via liver cancer stem cell activation
11/26/2024 7:20:29 AM | Browse: 6 | Download: 12
2
Enhancing the functionality of mesenchymal stem cells: An attractive treatment strategy for metabolic dysfunction-associated steatotic liver disease?
10/25/2024 2:40:46 AM | Browse: 13 | Download: 30
3
Predictive value of serum alanine aminotransferase for fatty liver associated with metabolic dysfunction
7/26/2024 10:33:29 AM | Browse: 29 | Download: 120
4
Exploring non-invasive diagnostics for metabolic dysfunction-associated fatty liver disease
7/24/2024 6:41:09 AM | Browse: 29 | Download: 107
5
Role of gut-liver axis and glucagon-like peptide-1 receptor agonists in the treatment of metabolic dysfunction-associated fatty liver disease
6/21/2024 3:14:32 AM | Browse: 37 | Download: 114
6
Screening for metabolic-dysfunction associated fatty liver disease: Time to discard the emperor's clothes of normal liver enzymes?
6/6/2024 5:43:14 AM | Browse: 75 | Download: 212
7
Current remarks and future directions on the interactions between metabolic dysfunction-associated fatty liver disease and COVID-19
3/21/2024 11:37:41 AM | Browse: 106 | Download: 259
8
Cumulative effects of excess high-normal alanine aminotransferase levels in relation to new-onset metabolic dysfunction-associated fatty liver disease in China
3/14/2024 5:31:16 PM | Browse: 91 | Download: 349
9
Impact renaming non-alcoholic fatty liver disease to metabolic associated fatty liver disease in prevalence, characteristics and risk factors
8/22/2023 7:39:26 AM | Browse: 138 | Download: 559
10
Interplay between metabolic dysfunction-associated fatty liver disease and chronic kidney disease: Epidemiology, pathophysiologic mechanisms, and treatment considerations
10/18/2022 8:29:59 AM | Browse: 355 | Download: 762
11
Immunotherapy for nonalcoholic fatty liver disease-related hepatocellular carcinoma: Lights and shadows
9/9/2022 12:48:14 PM | Browse: 321 | Download: 788
12
Hepatocellular carcinoma in patients with metabolic dysfunction-associated fatty liver disease: Can we stratify at-risk populations?
2/22/2022 9:25:37 AM | Browse: 476 | Download: 904
13
Nonalcoholic fatty liver disease shows significant sex dimorphism
2/11/2022 5:55:19 AM | Browse: 369 | Download: 1016
14
De novo and recurrence of metabolic dysfunction-associated fatty liver disease after liver transplantation
12/27/2021 5:24:00 AM | Browse: 418 | Download: 715
15
Effects of intragastric balloon placement in metabolic dysfunction-associated fatty liver disease: A systematic review and meta-analysis
7/23/2021 8:10:13 AM | Browse: 474 | Download: 1453
16
Individualized treatment options for patients with non-cirrhotic and cirrhotic liver disease
5/13/2021 10:05:39 AM | Browse: 435 | Download: 1052
17
COVID-19 severity in obesity: Metabolic dysfunction-associated fatty liver disease in the spotlight
4/21/2021 5:56:26 AM | Browse: 562 | Download: 1005
18
Validation of genetic variants associated with metabolic dysfunction-associated fatty liver disease in an ethnic-Chinese population
12/18/2020 5:58:43 AM | Browse: 597 | Download: 1337
Write to the Help Desk
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345